Companies: 10,795·Total market cap: $144.5T
ResMed Inc.

ResMed Inc.

RMDNYSEHealthcare● Active
$196.04
+$1.72(+0.89%)
Market Cap$28.4B
P/E Ratio
52W High$293.81
52W Low$180.27
Overview

ResMed Inc. (RMD) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

rmd · stock forecast · 35 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 35 Wall Street analysts in the past 3 months

SellBuy

Buy

35 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
16
Hold
14
Sell
5
Strong Sell
0
Total: 35 · Buy rate: 45.7%

12-Month Price Target

High

$345

Consensus

$281

+43.5% upside

Low

$225

Median: $275 · Last Close: $196.04

The ResMed Inc. (RMD) analyst consensus is Buy, based on ratings from 35 Wall Street analysts over the past 3 months. The average 12-month RMD price target is $281.29, representing +43.5% upside from the current price of $196.04.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $281 (43.5%)

Consensus Target

$281.29

43.5% upside

High Target

$345

76.0%

Low Target

$225

14.8%

Current Price

$196.04

as of today

Based on analyst price targets, the RMD stock price prediction for the next 12 months ranges from $225 to $345. The consensus RMD price forecast of $281.29 implies 43.5% upside from the current price of $196.04.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$186.614.81%

1-day model range: $185.64–$187.58. Peak: $187.58 (-4.81%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$215+9.7%
2028$229+16.7%
2029$238+21.5%
2030$245+24.7%
2031+26.9%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%8%71%
3Buy
1Neutral
10Sell
RSI (14)44.0Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · RMD · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$189.22BUY
MA 10$196.22SELL
MA 20$200.45SELL
MA 50$212.74SELL
MA 100$232.02SELL
MA 200$246.63SELL
Current $RMD · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$192.93BUY
EMA 10$195.25BUY
EMA 20$200.10SELL
EMA 50$211.83SELL
EMA 100$224.76SELL
EMA 200$235.85SELL
Current $RMD · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
RBC Capital2026-05-01
Maintains
OutperformOutperform
Wells Fargo2026-05-01
Maintains
Equal WeightEqual Weight
Keybanc2026-04-27
Maintains
OverweightOverweight
Citigroup2026-04-09
Maintains
BuyBuy
Citigroup2026-02-02
Maintains
BuyBuy
RBC Capital2026-01-30
Maintains
OutperformOutperform
Wells Fargo2026-01-30
Maintains
Equal WeightEqual Weight
Stifel2026-01-30
Maintains
HoldHold
Piper Sandler2026-01-30
Maintains
NeutralNeutral
Stifel2025-12-18
Maintains
HoldHold

Wall Street analysts have recently issued updated ratings on ResMed Inc. (RMD) stock. Of the recent 208 rating actions, 53 were upgrades and 40 were downgrades. 35 analysts currently cover RMD.

Analyst Recommendation Trends

Buy ratings11
Hold ratings01↑ +1
Sell ratings00

RMD analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$5.7B

↓ 13.0% YoY

Revenue Next Year

$6.1B

↑ 7.6% YoY

EPS This Year

$11.11

EPS Next Year

$12.24

↑ 10.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast RMD EPS of $11.11 for the current fiscal year, based on estimates from 9 analysts. The RMD revenue forecast is $5.7B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The RMD stock forecast is supported by two independent data sources: analyst consensus ratings from 35 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RMD price target is $281.29 (+43.5% upside), with an analyst consensus of Buy.

The RMD short-term stock prediction for tomorrow is $186.61 (-4.81%). The RMD stock price prediction for 2027 estimates an average of $215. The RMD stock prediction for 2030 projects a range of $234–$255.

ResMed Inc. trades on NYSE under the ticker RMD. The RMD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 46% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

RMD forecast · 8 questions

According to 35 Wall Street analysts, the average 12-month RMD price target is $281.29, with a high forecast of $345.00 and a low of $225.00. The median price target is shown in the chart above when available. This implies +43.5% potential upside from the current price of $196.04.

RMD price targetWhat is RMD price targetRMD analyst price targetRMD 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.